The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Alliance EAY191-A6: FOLFOX in combination with binimetinib as second-line therapy for patients with advanced biliary tract cancers (BTCs) with MAPK pathway alterations: A ComboMATCH treatment trial.
 
Ardaman Shergill
Honoraria - ASCO; Cholangiocarcinoma Foundation; cholangiocarcinoma summit; Colon Cancer Alliance; Curio Science; oklahoma society of clinical oncology; OncLive/MJH Life Sciences; saint joseph hospital Chicago
Consulting or Advisory Role - Catalyst Pharmaceuticals; Guardant Health; KLJ Associates; Pfizer; Pfizer; Triptych Health Partners
Research Funding - Astellas Pharma (Inst); BMS (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Gossamer Bio (Inst); Gritstone Bio (Inst); Hutchison MediPharma (Inst); Macrogenics (Inst); Merck (Inst); Oncologie (Inst); Pfizer (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TP Therapeutics (Inst); verastem (Inst)
Travel, Accommodations, Expenses - colon cancer alliance; Takeda
 
Chih-Yi Liao
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Boston Scientific; Exelixis; Genentech; Histosonics; Incyte; Ipsen; Lexicon; Lilly; QED Therapeutics; TransThera Biosciences
Speakers' Bureau - AstraZeneca; Eisai; Exelixis; Incyte
Research Funding - Bristol-Myers Squibb
Travel, Accommodations, Expenses - AstraZeneca; Eisai; Exelixis; Incyte; Ipsen
 
Mohamed I. Elsaid
Honoraria - Chronic Liver Disease Foundation
Research Funding - AstraZeneca (Inst)
 
Tareq Al Baghdadi
Stock and Other Ownership Interests - Bristol-Myers Squibb; Epizyme; HERON
Honoraria - Cardinal Health
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Cardinal Health; Genentech/Roche; Kite, a Gilead company; Lilly
 
Yan Ji
Consulting or Advisory Role - AstraZeneca; BeiGene; Janssen
 
Diane Feldman
No Relationships to Disclose
 
Suzanne George
Stock and Other Ownership Interests - Abbott Laboratories
Honoraria - CStone Pharmaceuticals
Consulting or Advisory Role - Bayer; BioAtla; Blueprint Medicines; Daiichi; deciphera; Immunicum; Kayothera; Lilly; MORE Health; Research to Practice; UpToDate
Research Funding - Acrivon Therapeutics; BioAtla; Blueprint Medicines (Inst); Daiichi Sankyo RD Novare (Inst); Deciphera (Inst); Eisai (Inst); IDRx (Inst); Merck (Inst); NewBay Pharma (Inst); SpringWorks Therapeutics (Inst); Theseus Pharmaceuticals (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - UptoDate
Expert Testimony - Bayer
Other Relationship - Research to Practice; WCG
 
Eileen M. O'Reilly
Consulting or Advisory Role - Abbvie (I); AstraZeneca; Autem Medical (I); Berry Genomics (I); BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Eisai (I); Exelixis (I); Genentech/Roche (I); Ipsen; J-Pharma (I); Merck; Merus; Novartis; QED Therapeutics (I); SERVIER (I); Tempus; Vector Health (I); Yiviva (I)
Research Funding - Agenus (Inst); Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Bristol Myers Squibb (Inst); Digestive Care (Inst); Elicio Therapeutics (Inst); Genentech (Inst); Helsinn Healthcare (Inst); Parker Institute for Cancer Immunotherapy (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Yiviva (Inst)
(OPTIONAL) Uncompensated Relationships - Thetis Pharma
 
Jeffrey A. Meyerhardt
Research Funding - Boston Biomedical (Inst)
 
Stephanie A. Berg
Honoraria - Aptitude Health; MJH Life Sciences
Consulting or Advisory Role - Bristol Meyers Squibb; Eisai; Exelixis; Exelixis; Genzyme; Myovant Sciences; Pfizer; Seattle Genetics/Astellas
 
Gary K. Schwartz
Stock and Other Ownership Interests - Bionaut Labs; GenCirq; January Therapeutics
Consulting or Advisory Role - AADi; Agenus; Astex Pharmaceuticals; Bionaut Labs; Boehringer Ingelheim; Concarlo; Gencirq; Ipsen; January Therapeutics; Kirilys Therapeutics; Oncogenuity; OnCusp Therapeutics; PureTech; Shanghai Pharma
Research Funding - Astex Pharmaceuticals; Oxford BioTherapeutics (Inst); PTC Therapeutics (Inst); Rain Therapeutics (Inst); SpringWorks Therapeutics (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Companion diagnostics for CD4 inhibitors (Inst); patent granted to develop a new technology called PNAs for cancer therapy
Travel, Accommodations, Expenses - Boehringer Ingelheim
 
Pamela N. Munster
Leadership - Alessa Therapeutics
Stock and Other Ownership Interests - Alessa Therapeutics; AtlasMedx; Hap10; OnKure; Parthenon Therapeutics; RasCal
Honoraria - JNJ; Olema Pharmaceuticals; Parthenon Therapeutics
Consulting or Advisory Role - Alessa Therapeutics; AtlasMedx; Olema Pharmaceuticals; RasCal
Research Funding - Actuate Therapeutics (Inst); Amgen (Inst); Arch Oncology (Inst); Arvinas (Inst); Arvinas (Inst); Bliss Biopharmaceutical (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Cyteir; Deciphera (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); IgM Biosciences (Inst); Immune Design (Inst); InventisBio (Inst); Merck (Inst); Novartis (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); PMV Pharma (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Sanofi (Inst); Seagen (Inst); Skorpion (Inst); Tempest Therapeutics (Inst); Xencor (Inst); Xynomic Pharma (Inst)
Patents, Royalties, Other Intellectual Property - UCSF patent on using silastic implants to deliver anticancer agents
Other Relationship - ABIM Subspecialty Board; NIH/NCI
 
Tanios S. Bekaii-Saab
Consulting or Advisory Role - Abbvie; Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca; Bayer (Inst); BeiGene; Boehringer Ingelheim; Caladrius Biosciences; Caladrius Biosciences; Celularity; Daiichi Sankyo/UCB Japan; Deciphera; Eisai; Eisai; Exact Sciences; Foundation Medicine; Foundation Medicine; Illumina; Immuneering; Incyte (Inst); Ipsen (Inst); Janssen; Kanaph Therapeutics; Lilly (Inst); Natera; Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); SOBI; Stemline Therapeutics; Treos Bio; Zai Lab
Patents, Royalties, Other Intellectual Property - Patent WO/2018/183488; Patent WO/2019/055687
Other Relationship - 1Globe Health Institute; AstraZeneca; Exelixis; FibroGen; Imugene; Lilly; Merck (Inst); Pancreatic Cancer Action Network; Replimune; Sun Biopharma; Suzhou Kintor Pharmaceuticals; UpToDate; Xilis
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - Abbvie; AstraZeneca; Autem Medical; Berry Genomics; BioNtech (I); Boehringer Ingelheim (I); Bristol-Myers Squibb/Medarex (I); Eisai; Exelixis; Ipsen; J-Pharma; Merck Serono (I); Merus NV (I); Neogene Therapeutics (I); Novartis (I); QED Therapeutics; Roche/Genentech; Servier; Tempus (I); Vector Health; Yiviva
Research Funding - Agenus (Inst); Arcus Ventures (Inst); AstraZeneca (Inst); BioNtech (Inst); Bristol-Myers Squibb (Inst); Elicio Therapeutics (Inst); Genentech/Roche (Inst); Helsinn Healthcare (Inst); Parker Institute for Cancer Immunotherapy (Inst); Pertzye (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Yiviva (Inst)
 
Rachna T. Shroff
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Genentech; Jazz Pharmaceuticals; Merck; Merus
Research Funding - Actuate Therapeutics; Bristol-Myers Squibb; Exelixis; Faeth Therapeutics; Fujifilm; Immunovaccine; Lisata; Loxo/Lilly; Merck; NGM Biopharmaceuticals; Novocure; Nucana; Rafael Pharmaceuticals; Seagen
 
Geoffrey Ira Shapiro
Consulting or Advisory Role - Bicycle Therapeutics; Merck Serono; Xinthera
Research Funding - Bristol-Myers Squibb/Medarex (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Pfizer (Inst); Tango Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Patent # 10,934,593 B2 Compositions and methods for predicting response and resistance to CDK4/6 inhibition; Patent #: 9872874 Title: Dosage regimen for sapacitabine and seliciclib Issue Date: 1/23/2018